Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05487170 · ClinicalTrials.gov registry record · Phase 1

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

A Phase 1 study of Advanced Solid Tumor and DLBCL, sponsored by Ranok Therapeutics (Hangzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
5
Study locations

NCT05487170 is a Phase 1 study of Advanced Solid Tumor and DLBCL that is actively recruiting participants, run by Ranok Therapeutics (Hangzhou) Co.. The registered enrollment target is 32 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05487170, a Phase 1 study of Advanced Solid Tumor and DLBCL, is actively recruiting participants, sponsored by Ranok Therapeutics (Hangzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
5
Study locations

Study Summary

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

Conditions Studied

Advanced Solid Tumor DLBCL

Interventions

  • DRUG RNK05047

Study Locations (5)

Beijing Municipality

  • Cancer Hospital, Chinese Academy of Medical Sciences - Beijing
  • Beijing Cancer Hospital - Beijing

Georgia

  • Emory University Winship Cancer Institute - Atlanta

Kentucky

  • Norton Cancer Institute - Louisville

New York

  • Weill Cornell - NY Presbyterian Hospital - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-07-12
Est. Completion 2025-09-01
Phase Phase 1

Sponsor

Ranok Therapeutics (Hangzhou) Co.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05487170

The ClinicalTrials.gov registry entry for NCT05487170 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (83% lower). The listed sponsor is Ranok Therapeutics (Hangzhou) Co., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which RNK05047 is the first listed.

NCT05487170 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Beijing Municipality, Georgia, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05487170 about?

NCT05487170 is a clinical study titled "A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)". This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL...

What is the current status of trial NCT05487170?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-07-12. Estimated completion is 2025-09-01.

What conditions does trial NCT05487170 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, DLBCL.

What interventions are being tested in trial NCT05487170?

The interventions under investigation include: RNK05047 (DRUG).

Who is sponsoring clinical trial NCT05487170?

This trial is sponsored by Ranok Therapeutics (Hangzhou) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05487170 being conducted?

This trial has 5 study locations across Georgia, Kentucky, New York, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

DLBCL

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.